Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262120 | 0.74 | FFAR3 (0.34) | GAAFFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL262225 | 0.73 | GAA (0.46) | GAAFFAR3ALDH1A1TSHR | |
| SCHEMBL7454835 | 0.69 | HDAC3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1525041 | 0.69 | HDAC3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Ethyl Acetate SCHEMBL26597081 | 0.68 | ALDH1A1 (0.50) | GAAFFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL5270259 | 0.67 | HDAC3 (0.43) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Alcohol SCHEMBL12986864 | 0.67 | GAA (0.50) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL27734974 | 0.67 | HDAC1 (0.39) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28023339 | 0.66 | GAA (0.54) | GAAALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL23501497 | 0.66 | HDAC3 (0.42) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595466-B2 | NKR variants for increased production of isobutanol | GEVO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230332130-A1 | ACETOLACTATE DECARBOXYLASE | INTERNATIONAL N&H DENMARK APS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230295601-A1 | ALDC PRODUCTION METHODS | INTERNATIONAL N&H DENMARK APS (DK) | 2023-09-21 | — | — | US | disclosed |
| CN-107636151-B | Acetolactate decarboxylase | 杜邦营养生物科学有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4155399-A1 | ACETOLACTATE DECARBOXYLASE | DuPont Nutrition Biosciences ApS (DK) | 2023-03-29 | — | — | EP | disclosed |
| US-20230087872-A1 | NOVEL NKR VARIANTS FOR INCREASED PRODUCTION OF ISOBUTANOL | GEVO, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11578316-B2 | Acetolactate decarboxylase variants having improved specific activity | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2023-02-14 | — | — | US | disclosed |
| EP-4114917-A1 | NOVEL NKR VARIANTS FOR INCREASED PRODUCTION OF ISOBUTANOL | GEVO, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3298138-B1 | ACETOLACTATE DECARBOXYLASE | DUPONT NUTRITION BIOSCI APS (DK) | 2022-08-10 | — | — | EP | disclosed |
| US-20210301279-A1 | ACETOLACTATE DECARBOXYLASE VARIANTS HAVING IMPROVED SPECIFIC ACTIVITY | INTERNATIONAL N&H DENMARK APS (DK) | 2021-09-30 | — | — | US | disclosed |
| US-8158404-B2 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8153415-B2 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8133715-B2 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011153144-A1 | ISOBUTANOL PRODUCTION USING YEASTS WITH MODIFIED TRANSPORTER EXPRESSION | GEVO, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011142865-A2 | YEAST MICROORGANISMS WITH REDUCED BY-PRODUCT ACCUMULATION FOR IMPROVED PRODUCTION OF FUELS, CHEMICALS, AND AMINO ACIDS | GEVO, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275129-A1 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110236942-A1 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110201090-A1 | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids | GEVO, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201072-A1 | Modified alcohol dehydrogenases for the production of fuels and chemicals | GEVO, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201073-A1 | Reduced by-product accumulation for improved production of isobutanol | GEVO, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595466-B2 | NKR variants for increased production of isobutanol | TKT, DCXR, AKR1C1 | GAA 2436/4885FFAR3 768/4885HDAC3 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.